CBER Updates Procedures for Fast Track, Breakthrough Designations
CBER has updated two standard operating procedures governing the designation and management of investigational products under the Fast Track and Breakthrough Therapy programs.
Both procedures took effect 11/19 and describe how CBER staff evaluate designation requests, coordinate expedited development activities and determine whether previously granted designations should be rescinded.
The revised Fast Track procedure (SOPP 8216) directs CBER to acknowledge designation requests within 14 calendar days and notify sponsors of its decision within 60 days. It also describes opportunities for more frequent interactions with FDA review teams, potential rolling review of marketing applications and eligibility for other expedited review mechanisms.
The updated Breakthrough Therapy procedure (SOPP 8212) addresses designation requests for drugs showing preliminary clinical evidence of substantial improvement over available therapies for serious conditions. It outlines review-team responsibilities, sponsor interactions and procedures for managing designated development programs.
Both documents address circumstances in which CBER may rescind a designation if the applicable criteria are no longer met, including notification to sponsors and opportunities to provide supporting information.
Both procedures were updated due to an earlier CBER reorganization.